Drug Trial Radar · NCT03728634
Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).
Last checked: Nov 20, 2026Latest source record: Dec 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Dec 21, 2018
Primary completion
Feb 20, 2020
Study completion Feb 20, 2020
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Nov 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability, as well as the pharmacokinetic and pharmacodynamic profiles of single and multiple doses of Eplontersen administered subcutaneously to healthy volunteers and patients with Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).
Conditions
- Healthy Volunteers
- hATTR Amyloidosis
Interventions
ION-682884Drug
ION-682884 administered SC
PlaceboDrug
Placebo comparator calculated volume to match ION-682884 administered SC
Vitamin ADietary supplement
Oral supplement
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: Up to Day 176
- Percentage of Participants Using Concomitant MedicationsTime frame: Up to Day 176
- Number of Participants With Clinically Significant Laboratory ValuesTime frame: Up to Day 176
- Number of Participants With Clinically Significant Physical Examination FindingsTime frame: Up to Day 176
- Number of Participants With Clinically Significant Electrocardiogram (ECG) ValuesTime frame: Up to Day 176
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bio Pharma Services, Inc.
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.